Collaborations
Cell-line engineering company announces expansion of Pfizer collaboration
Published in Obesity and Diabetes Week, January 30th, 2006
Under the expanded agreement, Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein product candidate. The parties will also initiate a collaborative program to genetically engineer production cell lines.
"Our relationship with Pfizer has been exceptionally productive as evidenced by their expanded commitment to the ACE System," said Alistair Duncan, president and CEO of Chromos. "We look forward to continuing to work on multiple programs with Pfizer to take advantage of the unique features and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Clinical Trials
Rosiglitazone increases sc adipose tissue glucose uptake in parallel with perfusion - Diabetes Pathogenesis
Inflammatory mediators by abdominal adipose tissue may link obesity and insulin resistance - Diabetes Pathogenesis
PPARalpha activation increases AdipoR and reduces inflammation in adipose tissue - Obesity Pathogenesis
Activation of cAMP or PPARgamma pathway increases oxidation in white adipocytes - Surgical Technology
RYGB surgery is effective treatment for type 2 diabetes mellitus in morbidly obese - Apoptosis
Alcohol stimulates activated hepatic apoptosis in genetically obese mice - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
